Vascular anomalies can be broadly classified into vascular tumours (eg. infantile haemangioma) and vascular malformations. The two main categories of vascular malformations are slow-flow (venous, lymphatic and capillary malformations) or fast-flow (arteriovenous malformations and fistulas). The interventional management of vascular malformations is the primary minimally-invasive therapy which largely replaced the surgical approach. The use of accurate terminology to describe this heterogenous, occasionally overlapping group of disorders is crucial for proper management and research. Unfortunately, despite the major improvement in the clinical, genetic and therapeutic management of vascular anomalies, myths and misconceptions about the diagnosis and management of these anomalies continue to be surprisingly pervasive with frequent serious consequences.
An animal study, published ahead of print in the Journal of the American College of Cardiology, indicates that renal denervation delivered through high-intensity focused ultrasound (HIFU) extracorpeal renal denervation may be an alternative approach to managing resistant hypertension as it is associated with blood pressure reduction without significant morbidity or mortality.
Un estudio de Taiwán sugiere que quienes padecen hepatitis C crónica tendrían menos riesgo de desarrollar cáncer hepático si toman fármacos para reducir el colesterol. Esto no prueba que las estatinas previenen el cáncer y un científico ajeno al estudio dice que no hay motivo suficiente para recomendar el uso de esos fármacos para evitar el cáncer de hígado.
Aunque durante una histerectomía también se suelen extirpar los ovarios, un nuevo estudio sugiere que dejarlos intactos sería más beneficioso. Un equipo halló que la extirpación ovárica reducía el riesgo de cáncer de ovario, pero a la vez que potenciaba el riesgo de morir por otras causas más comunes.
The SEATTLE II study, which will investigate the safety and efficacy of ultrasound accelerated thrombolysis with the EkoSonic Endovascular System (EKOS Corporation) for the treatment of massive and submassive pulmonary embolism, has completed enrolment. SEATTLE II is a 150-patient, single-arm prospective study measuring the rapid reduction in right heart strain in a patient population with both massive and submassive pulmonary embolism.
Los procedimientos mínimamente invasivos para operar el corazón y extirpar los fibroides serían más económicos y causarían menos ausencias laborales que las cirugías convencionales.
Un nuevo estudio revela que algunos hospitales implantan filtros en los vasos sanguíneos de más de un tercio de sus pacientes que desarrollan coágulos que podrían llegar a los pulmones, pese a que aún no existen pruebas científicas de que el dispositivo salve vidas.
Los pacientes de diabetes que toman la clase más nueva de medicamentos para controlar los niveles de azúcar en la sangre tienen el doble de probabilidades de sufrir de pancreatitis que los que toman otros medicamentos para controlar el azúcar
Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced CE Mark approval for its Surefire Infusion System ST/LT and Surefire Specialty Catheters. The company will launch its latest line of microcatheters and specialty catheters for the interventional radiology and interventional oncology markets in Europe during the second quarter 2013, and immediately in New Zealand, where regulatory approval has also been granted
BSD Medical Corporation (BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 319% increase in sales of its MicroThermX® Microwave Ablation System (MicroThermX®) disposable SynchroWave antennas during the first five months of fiscal 2013, when compared to the first five months of fiscal 2012 sales of its SynchroWave antennas. BSD President Harold Wolcott stated, “This increase in sales of disposable antennas is indicative of the growing acceptance and use of MicroThermX® products in the ablation market
PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRxs Lung Volume Reduction Coils (LVRCs) for severe emphysema. Dr. Charlie Strange, of the Medical University of South Carolina, and Dr. Frank Sciurba, of the University of Pittsburgh and UPMC, treated the first US patients in the FDA-approved RENEW Study. The RePneu® LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population
The Spectranetics Corporation (SPNC) today announced final results from the PATENT (Photo-Ablation using the TURBO-Booster(R) and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease (PAD). There is currently no FDA-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem
Un dispositivo magnético implantado podría ofrecer una nueva opción de tratamiento a las personas con acidez crónica que no se controla con medicamentos, sugiere un pequeño estudio.
Societies form new foundation, collaborate on multicenter trial to improve patient care
Patients who received minimally invasive treatment with yttrium-90 (Y-90) radioactive beads to treat colorectal cancer that had spread to the liver lived almost a year longer compared to those who received the standard of care therapy, data presented at the 5th annual Symposium on Clinical Interventional Oncology, in collaboration with the International Symposium on Endovascular Therapy (ISET) has suggested.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos